Major Pharmaceutical Conferences and Courses: October to November 2022.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 261, doi. 10.1007/s40290-022-00437-9
- Publication type:
- Article
Works matching IS 11782595 AND DT 2022 AND VI 36 AND IP 4
Results: 6
1
2
A Structured Methodology to Assess Safety Signal Strength and Inform Causality Assessment.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 215, doi. 10.1007/s40290-022-00436-w
- By:
- Publication type:
- Article
3
Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 201, doi. 10.1007/s40290-022-00435-x
- By:
- Publication type:
- Article
4
Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 247, doi. 10.1007/s40290-022-00433-z
- By:
- Publication type:
- Article
5
Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 223, doi. 10.1007/s40290-022-00432-0
- By:
- Publication type:
- Article
6
An Industry Survey on Managing the Pharmacovigilance System Master File in a Global Environment: The Need for a Pragmatic Approach.
- Published in:
- Pharmaceutical Medicine, 2022, v. 36, n. 4, p. 233, doi. 10.1007/s40290-022-00422-2
- By:
- Publication type:
- Article